Approved for use through 10/31/2002. OMB 0651-0031*

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.

Substitute for	form	1449A/PTO	
----------------	------	-----------	--

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known					
Application Number	09/891,206				
Filing Date	June 26, 2001				
First Named Inventor	ATHERTON et al.				
Group Art Unit	1616				
Examiner Name	Unassigned PAK, J.				
Attorney Docket Number	PHARMA-131				

Sheet

			U.S. PATENT DOCUM	MENTS	
Examiner Initials	Cite No.1	U.S. Patent Document Kind Code ² Number (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
(0)	1	5,342,604	Wilson et al.	08-30-1994	
	2	5,714,631	Wilson et al.	02-03-1998	
1	3	5,902,825	Wei Jia	05-11-1999	
The second	4	5,968,976	Murrer et al.	10-19-1999	
7/1	5	6,027,737	Morris, Jr. et al.	02-22-2000	
1					<u> </u>
					1 M M
					<u> </u>
L					
L					2002 2002
					9 2 11
					156
					8
	ļ				
				£	

				FOF	REIG	N PATENT DOCU	MENTS		
E	0	Fore	eign Patent De	ocument		Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant	
	Cite No. ¹	Office ³	Number ⁴	Kind Co		or Applicant of Cited Document	Cited Document MM-DD-YYYY Passages or Relevant Figures Appear	Τ ₆	
COL	6	WIPO	WO 96/3	0029			10-03-1996		
	7	FR	2 493 7	704			11-07-1980		
	 	-	_						
-				-					
				- "					

Examiner Signature	googn	Date Considered	1/20/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

Substitute for form 1449A/PTO

Examiner

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Compl te if Known							
Application Number	09/891,206						
Filing Date	June 26, 2001						
First Named Inventor	ATHERTON et al.						
Group Art Unit	1616						
Examiner Name	□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □						
Attorney Docket Number	PHARMA-131						

20/

\$		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
w xaminer initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
0	8	Fernandez-GAVARRON et al., "Incorporation of 140-lanthanum into bones, teeth and hydroxyapatite", <u>Bone and Mineral 3</u> , 1998, pp. 283-291	
0	9	YANAGIHARA et al., "Synthesis of Lanthanide Carbonates", <u>Journal of the Less-Common Metals</u> , 167: 1991, pp 223-232	
	10	Guggino et al., "Bone remodeling signaled by a dihydropyridine- and phenylalkylamine-sensitive calcium channel", <u>Proc. Natl. Acad. Sci.</u> , 86:April 1999, pp. 2957-2960	
0	11	GRAFF et al., "A Possible Non-aluminum oral phosphate binder? A Comparative Study on Dietary Phosphorus Absorption", Research Communications in Molecular Pathology and Pharmacology, Sep. 1995, pp, 373-388, Vol 89, No. 3	
0	12	HERGESELL et al., Phosphate binders on iron basis: A new perspective?", <u>Kidney International</u> , 1999, pp. S-42-S-45, Vol. 56., Suppl. 73	
0	13	HUTCH SON et al., "Calcitrol, Lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy", Procedings of the ISPD '98 - The VIIIth Congress of the ISPD, August 28-26, 1998, pp. S408-S412	
\- <u></u>	14	KARPINSKI et al., "A dihydropyridine-Sensitive Calcium Chennel in Rodent Osteoblastic Celle", Galcif Tissue Int., 45: 1989, pp 54-97,	
0	15	J. MCCLURE et al., "The production of Calcification in connective Tissue and Skeletal Muscle Using Various Chemical Compounds", <u>Calicif Tiss, Res.</u> , 22: 1976, pp.129-135	
0	16	SHANKAR et al., "Activation and inactivation of the osteoclast Ca ^{2*} receptor by the trivalent cation, La ^{3*} , <u>Biochemicaland Biophysical Research Communications</u> , 187 (2): Sep. 16, 1992, pp 907-912	
0	17	ZIMMERMANN et al., "Inhibition of chondrogenesis and endochrondral mineralization in vitro by different calcium channel blockers", <u>European Journal of Cell Biology</u> , 1994, pp. 114-121, Vol 63	
- AP	18	Harris et al., "The Effect of Lanthanum Chloride and related Compounds on Calcification", Arch. int. Pharmacodyn. 1970, pp. 269-278, Vol. 186	
0	19	DOTY et al., "Morphological Evidence of gap Junctions Between Bone Cells", Calcif. Tissue Int., 1981, pp 509-512, Vol. 33	

Considered Signature EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MAY 1 0 2002 TECH CENTER 1600/2900

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A	(08_00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Lagrangian Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
Substitute for form 1449A/PTO

Complete if Known

INFORMATIO	N D	ISCL	osu	RE
STATEMENT	BY	APPI	LICA	NT

JUL 1 0 2002

(+) inside this box

(use as many sheets as necessary)

Sheet 1 of 1

Please type a plus

Complete if Known					
Application Number	09/891,206				
Filing Date	June 26, 2001				
First Named Inventor	ATHERTON et al.				
Group Art Unit	1616				
Examiner Name	Unassigned PAK, J.				
Attorney Docket Number	PHARMA-131				

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *				
M	AA	R.H. WASSERMAN et al., "Effect of Vitamin D ₃ on Lanthanum Absorption: Suggestive Evidence for a Shunt Path", <u>Calcium Metab. Bone Metab.</u> , <u>Bone Dis.</u> , <u>Proc. Eur. Symp. Calcif. Tissues 10th</u> , 1975, pp. 87-90		
A)	АВ	International Search Report dated May 17, 2002	_	
		RECEIVED		
		JUL 1 1 2002		
		TECH CENTER 1600/29	00	

Examiner Signature	Aller	Date Considered	1/20/03	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.